Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley sold 25,734 shares of the company’s stock in a transaction on Monday, October 11th. The stock was sold at an average price of $0.90, for a total value of $23,160.60. The sale was disclosed in a filing with the SEC, which is accessible through this link.
NASDAQ:ABEO opened at $0.88 on Thursday. The stock has a market cap of $89.11 million, a price-to-earnings ratio of -1.52 and a beta of 1.43. The business has a fifty day moving average of $1.19 and a 200-day moving average of $1.44. Abeona Therapeutics Inc has a 1 year low of $0.84 and a 1 year high of $3.79.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, July 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). Equities analysts expect that Abeona Therapeutics Inc will post -0.65 EPS for the current fiscal year.
Several research analysts have recently issued reports on ABEO shares. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 22nd. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, October 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $3.65.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Article: Determine Your Level of Risk Tolerance
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.